About Invetx
Invetx is a Healthcare company based in Boston (United States) founded in 2018 by Juergen Horn, and was acquired by Dechra in July 2024. Invetx has raised $86 million across 3 funding rounds from investors including Abcellera Biologics, Dechra and WuXi Biologics. Its chief executive, as recorded, is Juergen Horn. Invetx offers products and services including Monoclonal Antibodies and Half-Life Extension Technology. Its focus areas include HealthTech, Veterinary HealthTech, Biopharmaceuticals and Companion Animals. Its legal entity is Invetx, Inc. Its competitors include Gallant, Genvax Technologies and Loyal; 3 of its 3 listed competitors have raised funding.
Company details
Provider of pharmaceutical products like protein-based therapeutics for pets. The company has developed transformational therapies for humans and also for veterinary medicine. It develops monoclonal antibodies and other protein-based therapies in human medicine that can be used in the veterinary field.
- Headquarters Boston, United States
- Founders Juergen Horn
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website invetx.com
- Social LinkedIn
- Acquired by Dechra (Jul 2024)
- Legal Name Invetx, Inc.
- Total Equity Funding$86M (USD)
in 3 rounds
- Latest Funding Round$60.5M (USD), Series B
May 2022
- InvestorsAbcellera Biologics
& 9 more
- Acquired byDechra
(Jul 2024)
Products & Services of Invetx
Invetx offers a comprehensive portfolio of products and services, including Monoclonal Antibodies and Half-Life Extension Technology.
Treats animal diseases with extended-duration antibody therapies
Enhances monoclonal antibody effectiveness for pet treatments
Funding Insights of Invetx
Invetx has successfully raised a total of $86M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $60.5 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $86M
- Total Rounds 3
- Last Round Series B — $60.5M
- First Round $15.25M
(Feb 2020)
- Investors Count 9
All 3 funding rounds of Invetx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2022 | $60.5M | Series B | – | F-Prime Capital, Novo Holdings | |
| Sep 2020 | $10.25M | Series A | – | Casdin Capital | |
| Feb 2020 | $15.25M | Series A | – | Anterra Capital |
10 investors in total: 10 institutional.
Investors in Invetx
Invetx has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Abcellera Biologics, Dechra and WuXi Biologics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Tech focused growth stage VC firm investing in Europe & North America | 2012 | anterracapital.com | Amsterdam, Netherlands | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Investment advisory services are provided to financial clients. | 1986 | teklacap.com | Boston, United States | |
An AI-enabled platform is used for antibody discovery. | 2012 | abcellera.com | Vancouver, Canada | |
Protein therapeutics are developed and manufactured by WuXi Biologics. | 2008 | wuxibiologics.com | Shanghai, China | |
Veterinary pharmaceuticals and related products are manufactured globally. | 1997 | dechra.com | Northwich, United Kingdom |
Investor details for Invetx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Invetx
19 people are tracked at Invetx (6 in leadership, 8 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Juergen Horn | Founder & CEO | Leadership |
Krishnan Sampath | Chief Technology Officer (invetx * A Dechra Division) | Leadership |
Colin Giles | Chief Development Officer | Leadership |
Jeff Troderman | CFO & Inside Counsel | Leadership |
William Brondyk | Chief Scientific Officer | Leadership |
Leila Sevigny | Senior Director, Drug Discovery | Leadership |
Peter Lee | Director | Board & advisors |
Gaynor Hillier | Advisor | Board & advisors |
Jessica Alston | Director | Board & advisors |
Phil Austin | Director | Board & advisors |
Jason Akus | Director | Board & advisors |
Rebecca Sendak | Scientific Advisor | Board & advisors |
Marcus Remmers | Director | Board & advisors |
Joachim Hasenmaier | Director | Board & advisors |
Elizabeth Bosia | Principal Research Associate | Team |
Aashrita Rajagopalan | Senior Scientific Manager, Biologics CMC Development | Team |
Chris Nicholson | Bioanalytical Assay Manager | Team |
David Brake | USDA CVB Regulatory Consultant | Team |
Shivaanee Kothavale | Senior Research Associate | Team |
Complete people profiles for Invetx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Invetx
4 dated milestones of Invetx across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Invetx is founded.
- Funding First funding round of $15.2M.
- Funding Latest funding round, Series B, of $60.5M.
- Exit Acquired by Dechra.
Competitors of Invetx
Invetx has 3 listed competitors in our database, 3 of them funded. They include Gallant, Genvax Technologies and Loyal.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gallant.com | 2018 | Los Angeles, United States | $61.46M | Stem cell storage for canine regenerative therapy is offered. | ||
| genvax.com | 2021 | Ames, United States | $9.9M | Vaccines for animal diseases are developed using mRNA nanoparticles. | ||
| loyal.app | 2020 | Encinitas, United States | $31.97M | Mobile application development, data management, and advertising services are provided. |
Detailed competitors of Invetx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Invetx
The website of Invetx (invetx.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 5.8% vs previous month
Websites whose visitors overlap most with Invetx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| actionselling.com | 100% | 4.5K | #3,132,429 | View details | |
| instinct.vet | 84% | 25.7K | #1,169,030 | View details |
Top companies in Veterinary Digital Health
3 companies that operate in the same segment as Invetx (Veterinary Digital Health) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Practice and prescription management software is provided for veterinary professionals. | 2010 | Portland, Oregon, United States | USD 291.64 M | |||
Veterinary pharmacy services are delivered by VetSource to practices. | 2005 | Portland, Oregon, United States | USD 81.25 M | |||
App based platform providing veterinary services and clinical management solutions for veterinarians | 2018 | Beverly Hills, California, United States | USD 58.81 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Invetx
Complete news archive for Invetx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Invetx
Invetx was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Invetx is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Juergen Horn is the CEO of Invetx, as recorded in our data. They have also founded this company.
Invetx is a funded company, having raised a total of $86M across 3 funding rounds to date. The company's 1st funding round was a Series A of $15.25M, raised on Feb 2020.
Provider of pharmaceutical products like protein-based therapeutics for pets. The company has developed transformational therapies for humans and also for veterinary medicine. It develops monoclonal antibodies and other protein-based therapies in human medicine that can be used in the veterinary field.
Invetx's top competitors include Loyal, Gallant and Genvax Technologies.
Invetx offers Monoclonal Antibodies and Half-Life Extension Technology.
Invetx has 10 investors. Key investors include Abcellera Biologics, Dechra, WuXi Biologics, Anterra Capital, and Tekla Capital Management.
Invetx operates through Invetx, Inc..
Yes. Invetx was acquired by Dechra in July 2024.